-
Mashup Score: 4Impact of a Novel Digital Therapeutics System on... : Official journal of the American College of Gastroenterology | ACG - 9 month(s) ago
H. METHODS: We conducted a multicenter, single-arm, 48-week trial in 19 patients with biopsy-confirmed NASH. All patients received a DTx intervention with a newly developed smartphone application. The primary endpoint was change in the nonalcoholic fatty liver disease activity score (NAS) without worsening of liver fibrosis. The secondary endpoints included improvement of the NAS by ≥2 points without worsening of liver fibrosis, change in the body weight, and regression of fibrosis. RESULTS: After the 48-week DTx intervention, improvement of the NAS was observed in 68.4% (13/19) of patients. The mean change in the NAS from baseline to the end of the intervention was −2.05 ± 1.96 (P < 0.001 when compared with the threshold of −0.7). A decrease in the NAS by ≥ 2 points was achieved in 11 (57.9%). The average weight loss at the end of the intervention was 8.3% (P < 0.001). Reduction of the fibrosis stage was observed in 58.3% when the analysis was limited to patients with stage F2/3 fibro
Source: journals.lww.comCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 8NASH drug treatment development: challenges and lessons - 9 month(s) ago
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. Although NAFLD is tightly linked to obesity and type 2 diabetes, this liver disease also affects individuals who do not have obesity. NAFLD increases the risk of developing cardiovascular disease, chronic kidney disease, and certain extrahepatic cancers. There is currently no licensed pharmacotherapy for NAFLD, despite numerous clinical trials in the past two decades. Currently, the reason so few drugs have been successful in the treatment of NAFLD in a trial setting is not fully understood.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
New Review online — NASH drug treatment development: challenges and lessons, by Tilg, Byrne and Targher A wide range of mechanisms are being studied; ideal #NASH candidates should be safe and hepatoprotective+cardioprotective https://t.co/QiwTPypNUf #MASLD #MASH #LiverTwitter https://t.co/wKnEORh4gV
-
-
Mashup Score: 1Ionizing radiation promotes, whereas calorie restriction suppresses, NASH and hepatocellular carcinoma in mice - 9 month(s) ago
Exposure to ionizing radiation damages DNA, increasing the risk of cancer and causing concern around the use of therapeutic radiation in children. In rodents, caloric restriction reduces the incidenc…
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Time-restricted eating may be ‘promising management option’ in patients with NAFLD, NASH - 10 month(s) ago
Modifying the timing of daily energy intake may improve metabolic health and restore natural circadian rhythms among patients with nonalcoholic fatty liver disease, according to a review published in Gut.Citing challenges with drug discovery and a lack of therapeutic agents for NAFLD and nonalcoholic steatohepatitis, Thomas Marjot, MD, of the Oxford Center for Diabetes, Endocrinology and
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 12Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Endoscopic sleeve gastroplasty an effective option for patients with NASH, obesity - 10 month(s) ago
Endoscopic sleeve gastroplasty was more effective for weight loss than lifestyle modification alone in patients with nonalcoholic steatohepatitis and obesity, according to a speaker at EASL Congress.“Previous studies show how lifestyle intervention with a reduction of more than 10% of body weight promotes NASH resolution and fibrosis regression,” Javier Abad Guerra, MD, a
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Endoscopic sleeve gastroplasty an effective option for patients with NASH, obesity - 11 month(s) ago
Endoscopic sleeve gastroplasty was more effective for weight loss than lifestyle modification alone in patients with nonalcoholic steatohepatitis and obesity, according to a speaker at EASL Congress.“Previous studies show how lifestyle intervention with a reduction of more than 10% of body weight promotes NASH resolution and fibrosis regression,” Javier Abad Guerra, MD, a
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Boston Pharmaceuticals Present Positive Data for New NASH Treatment - 11 month(s) ago
BOS-580 is an investigational, proprietary, long-acting fibroblast growth factor 21 analog as a monthly and bi-weekly treatment for patients with NASH.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress. “As a physician, I know how important it is to provide patients with therapies that can be impactful across a broad population of individuals with NASH,
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement - 11 month(s) ago
Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results. “Resmetirom is an oral, once-daily liver-targeted [thyroid hormone receptor]-beta- selective agonist in development for NASH,” Stephen A.
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial https://t.co/5OKIJ4DKFB Official journal of the American College of Gastroenterology | ACG @AmCollegeGastro #DTx #NASH